250 related articles for article (PubMed ID: 15527323)
1. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
[TBL] [Abstract][Full Text] [Related]
2. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
3. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
4. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
5. High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization.
Fix A; Peter M; Pierron G; Aurias A; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2004 Jul; 40(3):266-70. PubMed ID: 15139005
[TBL] [Abstract][Full Text] [Related]
6. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
[TBL] [Abstract][Full Text] [Related]
7. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
[TBL] [Abstract][Full Text] [Related]
8. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma.
Komuro H; Valentine MB; Rowe ST; Kidd VJ; Makino S; Brodeur GM; Cohn SL; Look AT
J Pediatr Surg; 1998 Nov; 33(11):1695-8. PubMed ID: 9856898
[TBL] [Abstract][Full Text] [Related]
10. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
11. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Mosse YP; Greshock J; Margolin A; Naylor T; Cole K; Khazi D; Hii G; Winter C; Shahzad S; Asziz MU; Biegel JA; Weber BL; Maris JM
Genes Chromosomes Cancer; 2005 Aug; 43(4):390-403. PubMed ID: 15892104
[TBL] [Abstract][Full Text] [Related]
12. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
[TBL] [Abstract][Full Text] [Related]
13. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
14. No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
Hogarty MD; Winter CL; Liu X; Guo C; White PS; Look AT; Brodeur GM; Maris JM
Cancer Res; 2002 Nov; 62(22):6481-4. PubMed ID: 12438240
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.
Beheshti B; Braude I; Marrano P; Thorner P; Zielenska M; Squire JA
Neoplasia; 2003; 5(1):53-62. PubMed ID: 12659670
[TBL] [Abstract][Full Text] [Related]
18. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
